Study guide
27.1 EDC Design and Fit-for-Purpose Systems
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
27.1 EDC Design and Fit-for-Purpose Systems
Key Takeaways Explain This Topic AI
Validation is proportionate to intended use, risks and data importance.
Vendor documentation does not by itself prove trial-specific configuration works.
Edit checks support review but cannot guarantee correct clinical data.
Last updated: October 2026
EDC Design and Fit-for-Purpose Systems
Electronic data capture must support reliable trial information while protecting participants. For CCRA preparation, use ICH E6(R3) Annex 1 section 4 , together with the investigator and sponsor provisions. Country-specific electronic-record regulations can apply in practice, but FDA Part 11 and EU Annex 11 are not additional ACRP examination references, and EU Annex 11 is not a general clinical-trial counterpart to Part 11.
EDC Architecture vs. Paper Case Report Forms
In legacy paper trials, investigative sites completed three-part or four-part carbon-copy Case Report Forms. The CRA visited the site, hand-compared source records against paper forms, physically pulled the "sponsor copy," and mailed batches of paper to a central data management facility where double-data keying was performed. Query cycles routinely spanned two to four months.
EDC implementations vary; use appropriate security and documented controls for their intended trial use.
eCRF Structural Design and Standardization
EDC form design may use CDISC (Clinical Data Interchange Standards Consortium) standards, specifically the CDASH (Clinical Data Acquisition Standards Harmonization) model. Standard eCRF modules include:
Demographics & Baseline Characteristics: Age, sex, race, ethnicity.
Medical History & Physical Examination: Pre-existing conditions mapped chronologically.
Inclusion / Exclusion Criteria: Binary confirmation of eligibility parameters.
Study Intervention / Dosing Administration: Exact dose, lot number, infusion start/stop times.
Concomitant Medications: Trade/generic name, indication, dose, frequency, route, dates of use.
Adverse Events: Verbatim term, onset/resolution dates, severity, causality, action taken, outcome.
Protocol Deviations & Study Completion: Termination reasons, completion milestones.
Automated Edit Checks (Programmed Validation Rules)
A transformative advantage of EDC systems is the execution of automated edit checks programmed into the software logic. Checks operate according to the system design:
Range Checks: Flags physiologically impossible or statistically improbable values (e.g., entering a diastolic blood pressure of 450 mmHg or a human body temperature of 10°C triggers an immediate soft or hard warning).
Required-Field Checks: Identify missing information according to the system design, while permitting appropriate documentation of genuinely unavailable data.
Format Checks: Enforces uniform data syntax (e.g., an unambiguous date convention defined by the tool to prevent international confusion between month and day).
Cross-Form / Cross-Panel Consistency Checks: Flags logical contradictions across different eCRF modules (e.g., if the Adverse Event log records an event of "Deep Vein Thrombosis" on October 14, but the Concomitant Medication log contains a new prescription for therapeutic Heparin beginning October 10 with an indication of "DVT," an automated cross-panel query fires).
Prompt Data Entry Guidelines
Sponsor contracts and Clinical Monitoring Plans (CMPs) enforce strict Service Level Agreements (SLAs) for data entry timelines. The trial may specify that investigative sites transcribe primary source data into eCRFs within its documented deadline following the participant's completed visit. Rapid data entry is not merely an administrative preference; it is a vital safety prerequisite enabling medical monitors and pharmacovigilance teams to detect emerging drug toxicity signals in real time.
Fit-for-purpose systems, access and validation
The responsible party should document how a system is used, who manages it, relevant interfaces and validation status. Validation should be proportionate to intended use, risks and the importance of the data. A vendor certificate alone does not demonstrate that trial-specific forms, calculations and transfers work correctly. Verify requirements, test critical functions and maintain control of changes.
Users need individual attributable access and permissions appropriate to their role. Investigator staff permissions should be consistent with delegation and visible to the investigator. Shared credentials compromise attribution and must be addressed. Notify the responsible system administrator when access should be changed or revoked; the CRA should facilitate the response, not assume unrestricted administrative authority.
A compromised investigator account requires prompt containment, review of affected records and an appropriate correction/endorsement process. Do not delete the audit trail or simply re-sign without reviewing what occurred. Preserve evidence, assess participant/data impact and track corrective actions. An unauthorised signature is a significant integrity concern; the monitor should not independently declare criminal intent from the fact alone.
Document security, backup, disaster recovery and contingency procedures, testing them as appropriate. The design determines backup frequency, recovery needs and other controls; ICH does not prescribe daily geo-redundant cloud backups or a universal 10-minute logout. During downtime, maintain safe trial conduct and reliable contemporaneous records under the approved contingency process, then reconcile restored data without disguising entry timing.
Computer-Generated, Time-Stamped Audit Trails
The computerized audit trail is the cornerstone of regulatory data integrity. E6(R3) data governance calls for appropriate secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic records.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , ICH E9(R1) .